Operational Team & Board
 | Frank Douglas, PhD, MD Board Member Dr. Frank L. Douglas is a Partner at PureTech. Previously, he was Professor of the Practice at MIT, the Harvard-MIT Division of Health Sciences & Technology, and Executive Director of the MIT Center for Biomedical Innovation. Dr. Douglas was also a member of the Board of Management and Executive Vice President, Drug Innovation and Approval, and Chief Scientific Officer of Aventis SA, where he oversaw global pharmaceutical research, development and regulatory activities. Prior to his positions with Aventis, Dr. Douglas was EVP of Global Research at Hoechst Marion Roussel, EVP of Research and Development at Marion Merrel Dow, and SVP & Director of Research at CIBA-GEIGY. He also served as Chairman of the Executive Committee of the Science and Regulatory Section of the Pharmaceutical Research and Manufacturers Association (PhRMA), has been a member of the Scientific Advisory Board of the U.S. Food and Drug Administration, the Advisory Board of the Paul Ehrlich Foundation, and a member of the Board of Directors of Alantos, Gene Logic, Nitromed Inc., and Archemix Inc. Dr. Douglas has received the Lewis B. Russell Memorial Award from the American Heart Association, the J.W. von Goethe Frankfurt University Medal of Honor and was named the recipient of the Global Pharmaceutical R&D Director of the Year Award in 2001, and again in 2004. Throughout his career Dr. Douglas has led teams that have discovered, developed, or extended the indications of more than 20 drugs. As a senior executive, he pioneered organizational changes that were forerunners to the emerging field of Translational Medicine, and he introduced Chemical Biology Platforms to the pharma industry. |
 | Raju Kucherlapati, PhD Dr. Raju Kucherlapati is a Professor of Medicine and the Paul C. Cabot Professor of Genetics at Harvard Medical School and the first Scientific Director of the Harvard-Partners Center for Genetics and Genomics. He received his Ph.D. from the University of Illinois at Urbana. Formerly he served on the faculties of Princeton University, University of Illinois College of Medicine, and the Albert Einstein College of Medicine. He serves on the editorial board of the New England Journal of Medicine and was editor in chief of the journal Genomics. Dr. Kucherlapati was a founder of Abgenix, Cell Genesys, and Millennium Pharmaceuticals. He currently serves on the boards of Millennium Pharmaceuticals and Abgenix as well as on the board of privately held AVEO Pharmaceuticals. |
 | Daphne Zohar Board Member Ms. Daphne Zohar is the Founder and Managing Partner of PureTech Ventures, a Boston-based venture creation firm specializing in translating breakthrough research from top tier academic institutions into therapies that will impact human health. PureTech reviews approximately 800 academic projects each year and selects the most interesting of those to form companies around. PureTech's Partners include entrepreneurs and leaders from the top echelon of pharma, biotech and academia including Dr. Ronald Cape (founder, Cetus), Dr. Robert Langer (renowned MIT professor), Dr. Frank Douglas (former Chief Scientific Officer, Aventis), Dr. Bennett Shapiro (former EVP Worldwide Basic and External Research, Merck), and Dr. John Zabriskie (former CEO Pharmacia & Upjohn). Zohar was named one of the world's top young innovators who will shape the future of technology by MIT's Technology Review magazine and one of the top "40 under 40" by the Boston Business Journal. A successful entrepreneur, Zohar created PureTech and assembled a leading team to help implement her vision for the firm. She sits on the boards of Solace Pharmaceuticals (where she was founding CEO), Follica Inc. (where she is currently CEO), Endra, and Satori Pharmaceuticals(where she was founding CEO) |
 | David Steinberg Founding CEO, Board Member Mr. Steinberg has worked in the biopharmaceuticals industry for over 13 years. As a member of PureTech, Mr. Steinberg has been on the founding teams of Enlight Biosciences and Endra Inc. as founding CEO. Previously, he served as Chief Business Officer of portfolio company Follica, Inc., and VP of Operations for portfolio companies Satori Pharmaceuticals and Cellicon Biotechnologies. He serves on the Board of Directors of Endra Inc., Enlight Biosciences, and Cellicon Biotechnologies. Prior to joining PureTech, he was a strategy consultant with the Boston Consulting Group and Vertex Partners, focusing on R&D and product strategy and strategic alliances for Fortune 500 pharmaceutical and biotechnology firms. Mr. Steinberg also worked as a research associate in Procter and Gamble Pharmaceuticals' R&D organization. Mr. Steinberg received his BA in Biology with distinction from Cornell University and graduated with high honors from the University of Chicago Graduate School of Business with an MBA in strategy and finance. |
 | Jonathan Behr, PhD Dr. Behr is an Associate with PureTech Ventures unearthing and evaluating venture creation opportunities. Prior to joining PureTech as a full time employee, Dr. Behr was a technical consultant to Enlight Biosciences. Dr. Behr is part of the founding team of Endra Inc., an Enlight project. Dr. Behr completed his graduate work in the Biological Engineering Department at M.I.T., where he developed a wide variety of novel analytical tools to analyze protein glycosylation. The Howard Hughes Medical Institute awarded Dr. Behr a predoctoral fellowship to support the entirety of his Ph.D. studies, and while at M.I.T., Dr. Behr was awarded the seminal Outstanding Undergraduate Alumnus award from the Rice University Biological Engineering Department. Dr. Behr earned his B.S. in Biological Engineering at Rice University, and his Ph.D. in Biological Engineering at M.I.T. |